Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01553084 · ClinicalTrials.gov registry record · Phase 4
A Comparative Effectiveness & Long Term Health Study in Wisconsin Smokers
A Phase 4 study of Smoking Cessation and Smoking, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,086
- Enrollment target
- 2
- Study locations
NCT01553084: Completed Phase 4 study of Smoking Cessation and Smoking, sponsored by University of Wisconsin, Madison.
NCT01553084 is a Phase 4 study of Smoking Cessation and Smoking that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 1,086 participants, above the 469-participant average among 188 other Smoking Cessation trials with a reported enrollment target (132% higher). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01553084, a Phase 4 study of Smoking Cessation and Smoking, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,086 participants
- Enrollment target
- 2
- Study locations
Study Summary
The overall purpose of this research is two-fold. First, the two smoking cessation medication treatments with the strongest evidence of effectiveness have never been directly compared. This research will determine how these two treatments compare in effectiveness in a head-to-head trial, and which types of smokers benefit most from each. Second, much of the data on smoking and health come from studies from many years ago. Today's smokers differ from earlier smokers in many ways that could influence the impact of smoking on health (e.g., weight, sex, diet, socio-economic status); the proposed work will determine how smoking cessation affects cardiovascular and pulmonary health in today's smokers.
Primary Outcome
Self-reported total abstinence from any tobacco use (even a single puff) for the seven days preceding the target follow-up day, confirmed with an exhaled carbon monoxide reading of \<10 ppm..
Conditions Studied
Interventions
- DRUG Varenicline
- DRUG Nicotine Patch
- DRUG Nicotine lozenge
Study Locations (2)
Wisconsin
- University of Wisconsin Center for Tobacco Research and Intervention, School of Medicine and Public Health - Madison
- University of Wisconsin Center for Tobacco Research and Intervention, School of Medicine and Public Health - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,086 participants |
| Start Date | 2012-05 |
| Est. Completion | 2017-08 |
| Phase | Phase 4 |
What the finished NCT01553084 record still lists
NCT01553084 is an interventional study that assigns participants to a tested intervention. Its 1,086 participants enrollment target places it among the larger protocols in the corpus, above the 469-participant average among 188 other Smoking Cessation trials with a reported enrollment target (132% higher).
The record links to 3 conditions, with Smoking Cessation appearing as the primary indexed condition, and to 3 interventions - of which Varenicline is the first listed.
NCT01553084 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT01553084 about?
NCT01553084 is a clinical study titled "A Comparative Effectiveness & Long Term Health Study in Wisconsin Smokers". The overall purpose of this research is two-fold. First, the two smoking cessation medication treatments with the strongest evidence of effectiveness have never been directly compared. This research will determine how these two treatments compare in effectiveness in a head-to-head trial, and which t...
What is the current status of trial NCT01553084?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,086 participants. The study started on 2012-05. Estimated completion is 2017-08.
What conditions does trial NCT01553084 study?
This clinical trial studies the following conditions: Smoking Cessation, Smoking, Nicotine Dependence.
What interventions are being tested in trial NCT01553084?
The interventions under investigation include: Varenicline (DRUG), Nicotine Patch (DRUG), Nicotine lozenge (DRUG).
Who is sponsoring clinical trial NCT01553084?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01553084 being conducted?
This trial has 2 study locations across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01553084's enrollment target sits among peer trials
1,086 21st of 188 higher than 168 of 188 other Smoking Cessation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoking Cessation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Modifying Progesterone and Estradiol Levels to Prevent Postpartum Cigarette Smoking Relapse and Reduce Secondhand Smoke Exposure in Infants and Children
RECRUITING · Phase 4
-
The Options 2 Study
RECRUITING · Phase 4
-
Smoking Cessation Program in the Construction Sector
RECRUITING · Phase 4
-
The Avenues Study: Dual Use Cessation
RECRUITING · Phase 4
-
Using Multiphase Optimization Strategy (MOST) to Optimize a Cost-effective, Sustainable and Scalable Smoking Cessation Package for Smokers in HIV Clinical Care
RECRUITING · Phase 4
-
Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06671483 · 1,088 participants · Phase 3
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
- NCT07196722 · 1,092 participants · Phase 2
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- NCT06074068 · 1,080 participants · NA
Father-Focused Intervention for Reducing Family Violence and Symptoms in Children
- NCT07213804 · 1,080 participants · Phase 3
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia